Biogen reported Phase 2 success for litifilimab, an anti-BDCA2 antibody, as it looks to build immunology momentum around lupus. The company said the treatment improved skin lesions at 24 weeks, with 14.7% of patients reaching the trial’s response threshold (as described in the excerpt). The report positions the data as a potential pillar for Biogen’s immunology pipeline and highlights lupus as a continued focus for antibody-based immunomodulation. By surfacing efficacy in a defined clinical endpoint tied to skin involvement, Biogen is signaling progress toward a potential path in a category where durable differentiation matters. For investors and pipeline watchers, the key takeaway is that Biogen is pushing a next-stage lupus strategy with a dose-and-endpoint performance story strong enough to characterize as a “success” milestone in Phase 2.